JPRN-UMIN000005952
Completed
Phase 1
Phase I-II study of combination chemotherapy with Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancer - Phase I-II study of Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancer
Osaka university, faculty of medicine0 sites40 target enrollmentJuly 8, 2011
ConditionsClear cell or mucinous ovarian cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Clear cell or mucinous ovarian cancer
- Sponsor
- Osaka university, faculty of medicine
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients who have a history of severe hypersensitivity to drug. 2\)Patients with interstitial pneumonia. 3\)Patients who have mmasive ascites and/or pleural effusion. 4\)Patients who have severe infectious diseases. 5\)Patients with other malignant disease. 6\)Women at pregnant state or possibly pregnant women. 7\)Patients with mental diseases. 8\)Patients with symptomatic brain metastasis. 9\)Patients with severe coronary disease. 10\) Patients with uncontrollable diabetic disease. 11\)Patients with watery diarrhea. 12\)Patients with severe ileus. 13\)Patients with intestinal bleeding. 14\)Patients with positeve HBs antigen. 15\)Patients with severe medical complications. 16\)Patients with systematic edema. 17\)Patients who are considered inappropriate for this study by the doctor.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000004729School of Medicine, Keio University40
Completed
Phase 1
A phase I study of the combination chemotherapy of IRISOX (irinotecan/S-1/oxaliplatin) in gemcitabine-refractory pancreatic cancergemcitabine-refractory pancreatic cancerJPRN-UMIN000022964Kitasato University School of Medicine12
Completed
Phase 2
A Phase II study of combination chemotherapy with TS-1 and Trastuzumab for patients with HER2 positive advanced or recurrent gastric cancer.advanced or recurrent gastric cancerJPRN-UMIN000008220Osaka medical center for cancer and cardiovascular diseases20
Completed
Phase 2
A phase II study of combination chemotherapy with carboplatin plus S-1 in advanced lung squamous cell carcinomaung cancerJPRN-UMIN000006983Hamamatsu University School of Medicine50
Completed
Phase 2
A phase II study of combination chemotherapy with carboplatin plus S-1 in advanced and recurrence non small cell lung cancernon-small-cell lung cancerJPRN-UMIN000010189ational Hospital Organization Osaka20